Advertisement
Canada markets open in 3 hours 40 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7312
    +0.0015 (+0.20%)
     
  • CRUDE OIL

    82.70
    -0.11 (-0.13%)
     
  • Bitcoin CAD

    87,347.03
    -3,341.71 (-3.68%)
     
  • CMC Crypto 200

    1,362.41
    -20.17 (-1.46%)
     
  • GOLD FUTURES

    2,338.40
    0.00 (0.00%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,512.75
    -151.75 (-0.86%)
     
  • VOLATILITY

    16.20
    +0.23 (+1.44%)
     
  • FTSE

    8,087.34
    +46.96 (+0.58%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6814
    -0.0005 (-0.07%)
     

DaVita’s Valuation on September 17

DaVita’s Valuation on September 17

DaVita (DVA) is a biotechnology company focused on the discovery, development, and commercialization of specialist medicines to cater to the medical needs in rare diseases and other specialized conditions. DaVita reported non-GAAP EPS of $1.15 on revenues of $2.9 billion, a 6.9% growth YoY (year-over-year) compared to $2.7 billion in the second quarter of 2017.